Medherant positions itself for the next stage of its development with the appointment of a new CEO
Coventry, UK, 25th June 2019 / Medherant Limited (“Medherant”), the clinical-stage company developing innovative products for pain and CNS diseases using a unique transdermal delivery technology, TEPI Patch®, has appointed John Burt as...
Medherant runner up in BVCA Management Team Awards
Medherant enjoyed a great evening at the Midlands BVCA Management Team Awards last night. The awards featured a number of leading businesses based in the Midlands and we were proud to be awarded runner up in the Venture-backed Management Team categor...
Mercia invests £2.0 million in transdermal drug delivery specialist, Medherant
Coventry, UK, 21st May 2019 / Medherant Limited (“Medherant”), the clinical-stage developer of innovative transdermal delivery products for pain and CNS diseases using its unique TEPI Patch® technology, has today announced a new £2 million i...
Localised Pain Relief – Going straight to the source
Pain affects everyone at some time in their life, be it chronic arthritis or a one-off injury. Whilst the level of pain can vary hugely, even a small amount can significantly impact a person’s quality of life...
Medherant included in Silicone Republic Europe Start-up 100
Medherant has been included in the Silicone Republic Europe Start-up 100 for 2019 which looks at the companies to watch this year in e-commerce and fintech, deeptech, hardware and IoT, and medtech and life sciences. Despite Brexit uncertainty, the...
Medherant’s Year in Review – 2018
Last year was another busy year for Medherant with a significant milestone reached when we received positive results from the first clinical trials with our TEPI Patch® technology. We also received grant funding to develop plans for our own GMP...
Medherant announces positive Phase I results for its first transdermal drug delivery patch
Coventry, UK, 5th November 2018 / Medherant, a developer of innovative transdermal drug delivery treatments for pain and CNS diseases, has successfully completed two Phase I studies with its novel Ibuprofen TEPI Patch®. The ...
Innovate UK Awards Medherant a Medicines Manufacturing Grant
New funding to support manufacture of transdermal patches for clinical trials Coventry, UK, 3rd October 2018 / Medherant, a developer of innovative transdermal drug delivery treatments for pain and CNS diseases, has been awarded a Medicines M...
Medherant nominated for two CPhI Pharma Awards
Medherant has been shortlisted for the CPhI Pharma Awards in both the Formulation and Drug Delivery Devices categories for its TEPI Patch® technology. This year marks the 15th anniversary of the CPhI Pharma Awards which are among the ...
Patch up the pain: A case study in transdermal drug delivery
Dr Vasiliki Nikolaou and Prof David Haddleton discuss trandsdermal patches in MedNous Transdermal drug delivery systems have been used in different forms since ancient times. The first patch reached the market in 1981 for the treatment of motion s...